PMN — ProMIS Neurosciences Share News
0.000.00%
Last trade - 00:00ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary
ProMIS Neurosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
ProMIS Neurosciences Inc reports results for the quarter - Earnings Summary
ProMIS Neurosciences Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Promis Neurosciences Presents Positive Data From PMN310 Phase1a Clinical Trial At The 17Th Clinical Trials On Alzheimer’S Disease Conference
Brief: Promis Neurosciences Inc Appointed Neil Warma As The President & Chief Executive Officer Of Co
Brief: Promis Neurosciences Reports Top-Line Data From Phase 1A Alzheimer's Trial
Brief: Promis Neurosciences Announces Up To $122.7 Mln Private Placement Financing
Brief: Promis Neurosciences Achieves Milestone In Development Of Therapeutic Alpha-Synuclein Vaccine
Brief: ProMIS Neurosciences CEO Gail Farfel Steps Down
Brief: Promis Neurosciences Doses First Subjects In Phase 1A Clinical Trial To Treat Alzheimer’s Disease
Brief: ProMIS Neurosciences Q3 net income USD -2.4 million
Brief: Sphera Funds Management Reports About 10% Passive Stake In Promis Neurosciences
Brief: Promis Neurosciences Announces $20.4 Million Private Placement Financing
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford